Bjorn Oskarsson, MD
Neurology · Jacksonville, FLNPI 1770692154
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $19,568 of the $29,438 with a category attached, or 66.5%. Tanabe Pharma America, Inc. accounts for 64.1% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $14,098 and has fallen 53.3% since, to $6,590 in 2025.
Across 49 payments — averaging $600.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tanabe Pharma America, Inc.$19K
- Corcept Therapeutics$7K
- Biogen$4K
- UCB, Inc.$75
- Grifols Shared Services North America, Inc.$23
Across 147 payments — averaging $15,350 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$1.5M
- Genentech, Inc.$211K
- Tanabe Pharma America, Inc.$161K
- Mitsubishi Tanabe Pharma Development America, Inc.$153K
- Orion Corporation$112K
- Sanofi$109K
- plus $57K from 2 others
What the payments were for
- Consulting fees$19,56866%
- Speaking & faculty fees$5,40818%
- Travel & lodging$2,7169%
- Food & beverage$1,7466%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tanabe Pharma America, Inc. | 23 | $18,864 |
| Corcept Therapeutics | 10 | $6,515 |
| Biogen | 14 | $3,960 |
| UCB, Inc. | 1 | $75 |
| Grifols Shared Services North America, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$29,438 in reported general payments places this provider in the 85th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 158 | $2,145,228 |
| RelyvrioSod Phenylbutyrat/Taurursodiol | 34 | $434,238 |
| NuedextaDextromethorphan Hbr/Quinidine | 34 | $61,499 |
| Riluzole | 128 | $19,061 |
| Gabapentin | 22 | $961 |
| Escitalopram Oxalate | 38 | $437 |
| Baclofen | 20 | $284 |
| Paroxetine Hcl | 15 | $75 |
Paid to pharmacies, not to this prescriber.
Other neurology in Jacksonville
- Steven ToenjesJacksonville$695K
- Zhigao HuangJacksonville$613K
- Kalina SandersJacksonville$544K
- Syed AsadJacksonville$302K
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Matthew BakerNaples$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.